Workgroup Report: Review of Genomics Data Based on Experience with Mock Submissions—View of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee

Over the past few years, both the U.S. Food and Drug Administration (FDA) and the pharmaceutical industry have recognized the potential importance of pharmacogenomics and toxicogenomics to drug development. To resolve the uncertainties surrounding the use of microarray technology and the presentatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Leighton, John K., Brown, Paul, Ellis, Amy, Harlow, Patricia, Harrouk, Wafa, Pine, P. Scott, Robison, Timothy, Rosario, Lilliam, Thompson, Karol
Formato: Texto
Lenguaje:English
Publicado: National Institute of Environmental Health Sciences 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440783/
https://www.ncbi.nlm.nih.gov/pubmed/16581548
http://dx.doi.org/10.1289/ehp.8318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1440783/
https://www.ncbi.nlm.nih.gov/pubmed/16581548
http://dx.doi.org/10.1289/ehp.8318

Ejemplares similares